More recently, asciminib, a groundbreaking treatment for CML, has gained FDA approval as the first STAMP inhibitor, which offers a novel mechanism of action by targeting the myristoyl pocket of BCR::ABL1, proves effective in overcoming resistance to traditional TKIs, and demonstrates superior efficacy and a favorable safety profile in clinical trials (Akhtar et al., 2025; Choi, 2023). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.